Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. Sep 22, 2025; 16(3): 107954
Published online Sep 22, 2025. doi: 10.4291/wjgp.v16.i3.107954
Published online Sep 22, 2025. doi: 10.4291/wjgp.v16.i3.107954
Colorectal cancer tumor phenotypes associated with KRAS, NRAS, and BRAF hot-spot mutations
Omer Abdelgadir, Graduate School of Biomedical Science, University of Texas Medical Branch, Galveston, TX 77555, United States
Yong-Fang Kuo, School of Public and Population Health, University of Texas Medical Branch, Galveston, TX 77555, United States
M Firoze Khan, Anthony O Okorodudu, Jianli Dong, Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, United States
Yu-Wei O Cheng, Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH 44106, United States
Author contributions: Abdelgadir OA and Dong J designed the research study; Abdelgadir O, Kuo YF, and Dong J performed and validate the statistical analysis; Abdelgadir O, Kuo YF, Khan MF, Okorodudu AO, Cheng YWO, and Dong J performed the manuscript writing, review and editing; and all authors have read and agreed to the published version of the manuscript.
Institutional review board statement: This study was approved by the Medical Ethics Committee of University of Texas Medical Branch, approval No. 02-089.
Informed consent statement: No patient informed consent specific to this study was required due to the retrospective nature of the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: The data presented in this study are de-identified and available upon reasonable request from the corresponding author. The data are not publicly available due to patient confidentiality restrictions.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jianli Dong, MD, PhD, Professor, Department of Pathology, Director, Molecular Diagnostics Division, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555, United States. jidong@utmb.edu
Received: April 2, 2025
Revised: May 19, 2025
Accepted: August 1, 2025
Published online: September 22, 2025
Processing time: 171 Days and 15.2 Hours
Revised: May 19, 2025
Accepted: August 1, 2025
Published online: September 22, 2025
Processing time: 171 Days and 15.2 Hours
Core Tip
Core Tip: In colorectal cancer, the kirsten rat sarcoma viral oncogene homolog p.Gly12Val and p.Gly13Asp mutations were linked to advanced tumor stage, while the kirsten rat sarcoma viral oncogene homolog p.Gly12Asp and p.Gly12Val muta